Is participation in this Springfield clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma Clinical Trial in Springfield, MO

Q: Is NCT07504588 recruiting in Springfield, MO?

Yes, NCT07504588 is currently recruiting participants at its Springfield, MO location. This recurrent platinum-sensitive fallopian tube endometrioid adenocarcinoma clinical trial is actively enrolling qualified participants.

Q: How do I join the recurrent platinum-sensitive fallopian tube endometrioid adenocarcinoma clinical trial in Springfield?

To join this clinical trial in Springfield, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

About This Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma Study in Springfield

This phase II trial compares the effect of sacituzumab govitecan and bevacizumab to standard care (carboplatin, pegylated liposomal doxorubicin, and bevacizumab) in patients with ovarian cancer that has come back after an initial response to platinum therapy (platinum-sensitive), that has progressed after poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor maintenance therapy (recurrent), and that has a mutation in the BRCA1 or BRCA2 genes or is homologous recombination deficient. Sacituzumab govitecan is a monoclonal antibody, called sacituzumab, linked to a drug called govitecan. Sacituzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as TROP2 receptors, and delivers govitecan to kill them. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It also blocks a certain enzyme needed for cell division and DNA repair. Liposomal doxorubicin is a form of the anticancer drug doxorubicin that is contained inside very tiny, fat-like particles. Liposomal doxorubicin may have fewer side effects and work better than other forms of the drug. Giving sacituzumab govitecan and bevacizumab may kill more tumor cells than standard care (carboplatin, pegylated liposomal doxorubicin, and bevacizumab) in patients with recurrent platinum-sensitive ovarian cancers that have BRCA1/2 mutations or homologous recombination deficiency.

Sponsor: National Cancer Institute (NCI)

Who Can Participate

Inclusion Criteria

Patients must have histologic diagnosis of high grade serous or endometrioid epithelial ovarian cancer

Ovarian cancer = fallopian tube, ovarian, and primary peritoneal cancer

Disease must be platinum sensitive, as defined by progression documented ≥ 6 months (182 days) from the last receipt of platinum

Disease must have progressed during first line maintenance PARP inhibitor (PARPi) for advanced ovarian cancer. NO intervening therapies between progression on PARPi and study registration are permitted

Disease must be germline or somatic BRCA1 or BRCA2 mutated or homologous recombination deficiency test positive

Disease must be measurable or non-measurable as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v.) 1.1

Secondary or cytoreductive surgery, after start of treatment on this trial, and prior to documentation of disease progression, is NOT permitted

No previous receipt of any topoisomerase-I inhibiting agents

No investigational agents within 4 weeks of study registration

No current treatment with any other (non-study) cytotoxic chemotherapy, targeted therapy, biologic therapy, immunotherapy or endocrine therapy for the treatment of the disease under the current study

Last dose of PARP inhibitor treatment must be ≥ 3 weeks before study registration

Patients with treated brain metastases are eligible if follow-up brain imaging 4 weeks after CNS-directed therapy shows no evidence of disease progression. Patients with brain metastases must have follow up imaging demonstrating no evidence of disease progression and that the disease is stable off of steroids

Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2

Not pregnant and not nursing

Absolute neutrophil count (ANC) ≥ 1,500 cells/mm\^3

Platelets ≥ 100,000 cells/mm\^3

Hemoglobin ≥ 9 g/dl (Note: The use of transfusion or other intervention to achieve hemoglobin \[Hgb\] ≥ 9 g/dl is acceptable)

Creatinine clearance (CrCL) of ≥ 30 mL/min by the Cockcroft-Gault formula

Urinalysis with ≤ 1+ protein and/or urine protein \< 1.0 g/24 hours (hrs)

Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) (patients with known Gilbert's disease who have bilirubin level ≤ 3 x institutional ULN may be enrolled)

Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 x institutional ULN

Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association functional classification. To be eligible for this trial, patients should be class 2B or better

No active infection requiring parenteral antibiotics

No non-healing wound, ulcer, or bone fracture

No current evidence of intra-abdominal abscess, abdominal/pelvic fistula (not diverted), gastrointestinal perforation, gastrointestinal (GI) obstruction, and/or need for drainage nasogastric or gastrostomy tube

No clinically significant bleeding within 28 days prior to registration

No uncontrolled hypertension, defined as systolic ≥ 160 mm Hg or diastolic ≥ 100 mm Hg

Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities \> grade 1) with the following exceptions:

Patients with grade 2 or lower neuropathy, any grade alopecia, well controlled hypertension, thyroid disease controlled with therapy, and history of thromboembolic disease on anticoagulation are eligible

Patients with laboratory-based grade 2 or higher adverse events (AEs) that meet the criteria outlined above are eligible

No major surgery within 3 weeks prior to study registration

Patients who underwent major surgery must have recovered adequately from any toxicity and/or complications from surgery prior to study registration

No strong inhibitors or inducers of UGT1A1

No history of allergic reaction to the study agent(s), compounds of similar chemical or biologic composition to the study agent(s) (or any of its excipients)

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Springfield?

Yes, this clinical trial (NCT07504588) has an active research site in Springfield, MO that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma Treatment Options in Springfield, MO

If you're searching for recurrent platinum-sensitive fallopian tube endometrioid adenocarcinoma treatment options in Springfield, MO, this clinical trial (NCT07504588) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Springfield research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced recurrent platinum-sensitive fallopian tube endometrioid adenocarcinoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all recurrent platinum-sensitive fallopian tube endometrioid adenocarcinoma clinical trials near you to find additional studies recruiting in your area.

Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma Clinical Trial in Springfield, MO

Expert Care in Springfield

IRB Approved

No-Cost Care

Apply for This Springfield Location

Why Participate?

Simple Process